



BRIAN SANDOVAL
Governor

STATE OF NEVADA
DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
1100 E. William Street, Suite 101
Carson City, Nevada 89701
(775) 684-3676 • Fax (775) 687-3893

RICHARD WHITLEY, MS
Director

MARTA JENSEN
Acting Administrator

NOTICE OF PUBLIC MEETING – DRUG USE REVIEW BOARD

AGENDA

Date of Posting: March 24, 2016

Date of Meeting: Thursday, April 28, 2016 at 5:15 PM

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Drug Use Review Board (DUR).

Place of Meeting: Best Western Plus Airport Plaza Hotel
1981 Terminal Way
Reno, NV 89502
Phone: (775) 348-6370

Webinar Pre-Registration **Must Pre-Register**

<https://catamaranrx.webex.com/catamaranrx/onstage/g.php?MTID=e6806b5cfceaa7942bade987dec542650>

Or go to www.webex.com and enter the Event Number listed below.

Once you have registered for the meeting, you will receive an email message confirming your registration. This message will provide the information that you need to join the meeting.

Event Number: 742 034 472

Click “Join Now”

Follow the instructions that appear on your screen to join the audio portion of the meeting. Audio will be transmitted over the internet. No phone number is required.

AGENDA

1. **Call to Order and Roll Call**
2. **Public Comment on Any Matter on the Agenda**
3. **Administrative**
 - a. **For Possible Action:** Review and Approve Meeting Minutes from January 28, 2016.
 - b. Status Update by DHCFP
April 14, 2016 MSM Chapter 1200 public hearing
4. **Board Action**
 - a. **For Possible Adoption:** Discussion and possible adoption of coverage policy on medications used for the hormonal transition treatment for transgender individuals
 - i. Public comment on medication limitations/availability of hormones for transition treatment for transgender individuals
 - ii. Discussion by the Board and review of utilization data and current policy
 - iii. Possible adoption of updated drug coverage policy and criteria
 - b. **For Possible Action:** Discussion and adoption of coverage policy on allowance of pharmacist submitted prior authorizations.
 - i. Public comment on pharmacists submitting prior authorizations
 - ii. Discussion by the Board and review of utilization data and current policy
 - iii. Possible adoption of updated policy and criteria
 - c. **For Possible Action:** Discussion and adoption of coverage policy on use of brand name products when a generic is available and Dispense as Written requirements
 - i. Public comment on Brand name products when a generic is available.
 - ii. Discussion by the Board and review of utilization data and current policy
 - iii. Possible adoption of updated drug coverage policy and criteria
5. **Clinical Presentations**
 - a. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria for colony stimulating factors.
 - i. Public comment on adoption of policy.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by the Board and review of utilization data.
 - iv. Possible adoption of prior authorization criteria/policy.

- b. **For Possible Action:** Discussion and possible adoption of prior authorization criteria for eluxadoline (Viberzi®)
 - i. Public comment on proposed clinical prior authorization criteria.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by the Board and review of utilization data.
 - iv. Proposed adoption of updated prior authorization criteria.

- c. **For Possible Action:** Discussion and possible adoption of prior authorization criteria for doxylamine succinate/pyridoxine hydrochloride (Diclegis®).
 - i. Public Comment on proposed clinical prior authorization criteria.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by the Board and review of utilization data.
 - iv. Proposed adoption of updated prior authorization criteria

- d. **For Possible Action:** Discussion and possible adoption of prior authorization criteria for Neurokinin-1 (NK1) Receptor Antagonists and Combinations
 - i. Public comment on proposed clinical prior authorization criteria.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by Board and review of utilization data.
 - iv. Proposed adoption of updated prior authorization criteria.

- e. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria for medications used for opioid dependence.
 - i. Public comment on proposed clinical prior authorization criteria.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by Board and review of utilization data.
 - iv. Proposed adoption of updated prior authorization criteria.

- f. **For Possible Action:** Discussion and possible adoption of prior authorization criteria for medications used for opioid induced constipation.
 - i. Public comment on proposed clinical prior authorization criteria.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by Board and review of utilization data.
 - iv. Proposed adoption of updated prior authorization criteria.

- g. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria for long-acting opioids.
 - i. Public comment on proposed clinical prior authorization criteria.
 - ii. Presentation of utilization and clinical information.

- iii. Discussion by Board and review of utilization data.
- iv. Proposed adoption of updated prior authorization criteria.

6. Public Comment on any DUR Board Requested Report

7. DUR Board Requested Reports

- a. Cumulative acetaminophen report
 - i. Discussion by the Board and review of utilization data.
- b. Long-acting steroid inhaler combination utilization
 - i. Discussion by the Board and review of utilization data.
- c. Utilization of short-acting insulin without long-acting/basal insulin
 - i. Discussion by the Board and review of utilization data.
- d. Narcotic cough suppressants utilization
 - i. Discussion by the Board and review of utilization data.

8. Public Comment on any Standard DUR Report

9. Standard DUR Reports

- a. Review of Prescribing/Program Trends.
 - i. Top 10 Therapeutic Classes for Q3 2015, Q4 2015 and Q1 2016 (by Payment and by Claims).
 - ii. Top 50 Drugs of Q3 2015, Q4 2015 and Q1 2016 (by Payment and by Claims).
- b. Concurrent Drug Utilization Review (ProDUR)
 - i. Review of Q3 2015, Q4 2015 and Q1 2016.
 - ii. Review of Top Encounters by Problem Type.
- c. Retrospective Drug Utilization Review (RetroDUR)
 - i. Status of previous quarter.
 - ii. Status of current quarter.
 - iii. Review and discussion of responses.

10. Closing Discussion

- a. Public comments on any subject.
- b. Date and location of the next meeting.

- i. Discussion of the time of the next meeting.
- c. Adjournment.

PLEASE NOTE: Items may be taken out of order at the discretion of the chairperson. Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. If an action item is not completed within the time frame that has been allotted, that action item will be continued at a future time designated and announced at this meeting by the chairperson. All public comment may be limited to 5 minutes.

This notice and agenda have been posted at <http://dhcfnv.gov> and <http://notice.nv.gov>

Carson City Central office and Las Vegas DHCFP. The agenda posting of this meeting can be viewed at the following locations: Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the meeting materials will be mailed to you. Requests and/or written comments may be sent to Ellen Felsing at the Division of Health Care Financing and Policy, 1100 E. William Street, Suite 101, Carson City, NV 89701, at least three days before the public hearing.

All persons that have requested in writing to receive the Public Hearings agenda have been duly notified by mail or e-mail.

Note: We are pleased to make accommodations for members of the public who have disabilities and wish to attend the meeting. If special arrangements are necessary, notify the Division of Health Care Financing and Policy as soon as possible and at least ten days in advance of the meeting, by e-mail at ellen.felsing@dhcfnv.gov in writing, at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Robyn Heddy at (775) 684-3684.